Third-Line Trifluridine–Tipiracil Plus Bevacizumab ‘Represents New Standard Of Care’ For mCRC
From 2023 ASCO GI Cancers Symposium:
The SUNLIGHT trial shows a significant improvement in the overall survival of patients with refractory metastatic colorectal cancer with the addition of bevacizumab to trifluridine and tipiracil